The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis

2024-9-1

Single‐cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes

2024-9-1

Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up

2024-9-1

Are we ready for disease modification in myeloproliferative neoplasms?

2024-9-1

Issue Information

2024-9-1

Battle of the sexes: Understanding donor:recipient sex differences in transplantation biology

2024-9-1

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms

2024-8-1

Prognostic relevance of molecular measurable residual disease detection in AML with mutated <i>CEBPA</i>

2024-8-1

Don't call me “Sickler”: Confronting stigma in sickle cell disease

2024-8-1

The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study

2024-8-1

How to manage patients with germline <i>DDX41</i> variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms

2024-8-1

A cellular reporter system to evaluate endogenous fetal hemoglobin induction and screen for therapeutic compounds

2024-8-1

Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma

2024-8-1

Robust and cost‐effective CRISPR/Cas9 gene editing of primary tumor B cells in Eµ‐TCL1 model of chronic lymphocytic leukemia

2024-8-1

PD‐L1⁺ macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B‐cell lymphoma microenvironment impact CD19 CAR‐T cell immunotherapy efficacy

2024-8-1

What is lost when training goes digital?

2024-8-1

RNA binding protein‐directed control of leukemic stem cell evolution and function

2024-8-1

Improving CORM technology for the treatment of delayed hemolytic transfusion reaction

2024-8-1

Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab

2024-8-1

Bone marrow niches for hematopoietic stem cells

2024-7-31

Long‐term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome

2024-7-30

Disease‐burden‐adapted immunotherapy protocol for primary refractory or high‐risk relapsed pediatric acute lymphoblastic leukemia

2024-7-29

Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study

2024-7-29

Issue Information

2024-7-29

Less is more: Depleting myeloid‐biased HSCs to restore immune function

2024-7-1

Infections in patients with mantle cell lymphoma

2024-7-1

Different roles for different bones<b>—</b>Location matters for blood production

2024-7-1

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study

2024-7-1

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?

2024-7-1

Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)

2024-7-1

Oncogenic and immunological targets for matched therapy of pediatric blood cancer patients: Dutch iTHER study experience

2024-7-1

Exciting science from the 16th International Conference on Thalassemia and Hemoglobinopathies

2024-7-1

Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study

2024-7-1

Prospective genetic germline evaluation in a consecutive group of adult patients aged &lt;60 years with myelodysplastic syndromes

2024-7-1

Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities

2024-7-1

Parkinson‐like neurotoxicity in female patients treated with idecabtagene‐vicleucel

2024-7-1

Fibrinogen‐like 1: A hepatokine linking liver physiology to hematology

2024-7-1

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes

2024-7-1

Parents' perception of treatment‐related toxicity in children treated according to the NOPHO ALL2008 protocol for acute lymphoblastic leukemia

2024-7-1

Correction to “Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up”

2024-7-1

Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step‐up dosing

2024-7-1

Correction to “Influence of donor–recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation”

2024-7-1

Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia

2024-7-1

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma

2024-7-1

The role of trephine bone marrow biopsies in the era of measurable residual disease<b>—</b>Results from the CLL10 trial of the German CLL Study Group (GCLLSG)

2024-7-1

Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real‐world setting

2024-7-1

CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience

2024-7-1